The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity

Keith H. Nuechterlein, Michael F. Green, Robert S. Kern, Lyle E. Baade, Deanna M. Barch, Jonathan D. Cohen, Susan Essock, Wayne S. Fenton, Frederick J. Frese, James M. Gold, Terry Goldberg, Robert K. Heaton, Richard S E Keefe, Helena Kraemer, Raquelle Mesholam-Gately, Larry J. Seidman, Ellen Stover, Daniel Weinberger, Alexander S. Young, Steven ZalcmanStephen R. Marder

Research output: Contribution to journalArticle

Abstract

Objective: The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia through a broadly based scientific evaluation of measures. Method: The MATRICS Neurocognition Committee evaluated more than 90 tests in seven cognitive domains to identify the 36 most promising measures. A separate expert panel evaluated the degree to which each test met specific selection criteria. Twenty tests were selected as a beta battery. The beta battery was administered to 176 individuals with schizophrenia and readministered to 167 of them 4 weeks later so that the 20 tests could be compared directly. Results: The expert panel ratings are presented for the initially selected 36 tests. For the beta battery tests, data on test-retest reliability, practice effects, relationships to functional status, practicality, and tolerability are presented. Based on these data, 10 tests were selected to represent seven cognitive domains in the MATRICS Consensus Cognitive Battery. Conclusions: The structured consensus method was a feasible and fair mechanism for choosing candidate tests, and direct comparison of beta battery tests in a common sample allowed selection of a final consensus battery. The MATRICS Consensus Cognitive Battery is expected to be the standard tool for assessing cognitive change in clinical trials of cognition-enhancing drugs for schizophrenia. It may also aid evaluation of cognitive remediation strategies.

Original languageEnglish (US)
Pages (from-to)203-213
Number of pages11
JournalAmerican Journal of Psychiatry
Volume165
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Reproducibility of Results
Cognition
Schizophrenia
Consensus
Research
Clinical Trials
National Institute of Mental Health (U.S.)
Patient Selection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., ... Marder, S. R. (2008). The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. American Journal of Psychiatry, 165(2), 203-213. https://doi.org/10.1176/appi.ajp.2007.07010042

The MATRICS consensus cognitive battery, part 1 : Test selection, reliability, and validity. / Nuechterlein, Keith H.; Green, Michael F.; Kern, Robert S.; Baade, Lyle E.; Barch, Deanna M.; Cohen, Jonathan D.; Essock, Susan; Fenton, Wayne S.; Frese, Frederick J.; Gold, James M.; Goldberg, Terry; Heaton, Robert K.; Keefe, Richard S E; Kraemer, Helena; Mesholam-Gately, Raquelle; Seidman, Larry J.; Stover, Ellen; Weinberger, Daniel; Young, Alexander S.; Zalcman, Steven; Marder, Stephen R.

In: American Journal of Psychiatry, Vol. 165, No. 2, 02.2008, p. 203-213.

Research output: Contribution to journalArticle

Nuechterlein, KH, Green, MF, Kern, RS, Baade, LE, Barch, DM, Cohen, JD, Essock, S, Fenton, WS, Frese, FJ, Gold, JM, Goldberg, T, Heaton, RK, Keefe, RSE, Kraemer, H, Mesholam-Gately, R, Seidman, LJ, Stover, E, Weinberger, D, Young, AS, Zalcman, S & Marder, SR 2008, 'The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity', American Journal of Psychiatry, vol. 165, no. 2, pp. 203-213. https://doi.org/10.1176/appi.ajp.2007.07010042
Nuechterlein, Keith H. ; Green, Michael F. ; Kern, Robert S. ; Baade, Lyle E. ; Barch, Deanna M. ; Cohen, Jonathan D. ; Essock, Susan ; Fenton, Wayne S. ; Frese, Frederick J. ; Gold, James M. ; Goldberg, Terry ; Heaton, Robert K. ; Keefe, Richard S E ; Kraemer, Helena ; Mesholam-Gately, Raquelle ; Seidman, Larry J. ; Stover, Ellen ; Weinberger, Daniel ; Young, Alexander S. ; Zalcman, Steven ; Marder, Stephen R. / The MATRICS consensus cognitive battery, part 1 : Test selection, reliability, and validity. In: American Journal of Psychiatry. 2008 ; Vol. 165, No. 2. pp. 203-213.
@article{2f6dfbe8c80a42e5834c40e0ed1fc9c7,
title = "The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity",
abstract = "Objective: The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia through a broadly based scientific evaluation of measures. Method: The MATRICS Neurocognition Committee evaluated more than 90 tests in seven cognitive domains to identify the 36 most promising measures. A separate expert panel evaluated the degree to which each test met specific selection criteria. Twenty tests were selected as a beta battery. The beta battery was administered to 176 individuals with schizophrenia and readministered to 167 of them 4 weeks later so that the 20 tests could be compared directly. Results: The expert panel ratings are presented for the initially selected 36 tests. For the beta battery tests, data on test-retest reliability, practice effects, relationships to functional status, practicality, and tolerability are presented. Based on these data, 10 tests were selected to represent seven cognitive domains in the MATRICS Consensus Cognitive Battery. Conclusions: The structured consensus method was a feasible and fair mechanism for choosing candidate tests, and direct comparison of beta battery tests in a common sample allowed selection of a final consensus battery. The MATRICS Consensus Cognitive Battery is expected to be the standard tool for assessing cognitive change in clinical trials of cognition-enhancing drugs for schizophrenia. It may also aid evaluation of cognitive remediation strategies.",
author = "Nuechterlein, {Keith H.} and Green, {Michael F.} and Kern, {Robert S.} and Baade, {Lyle E.} and Barch, {Deanna M.} and Cohen, {Jonathan D.} and Susan Essock and Fenton, {Wayne S.} and Frese, {Frederick J.} and Gold, {James M.} and Terry Goldberg and Heaton, {Robert K.} and Keefe, {Richard S E} and Helena Kraemer and Raquelle Mesholam-Gately and Seidman, {Larry J.} and Ellen Stover and Daniel Weinberger and Young, {Alexander S.} and Steven Zalcman and Marder, {Stephen R.}",
year = "2008",
month = "2",
doi = "10.1176/appi.ajp.2007.07010042",
language = "English (US)",
volume = "165",
pages = "203--213",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - The MATRICS consensus cognitive battery, part 1

T2 - Test selection, reliability, and validity

AU - Nuechterlein, Keith H.

AU - Green, Michael F.

AU - Kern, Robert S.

AU - Baade, Lyle E.

AU - Barch, Deanna M.

AU - Cohen, Jonathan D.

AU - Essock, Susan

AU - Fenton, Wayne S.

AU - Frese, Frederick J.

AU - Gold, James M.

AU - Goldberg, Terry

AU - Heaton, Robert K.

AU - Keefe, Richard S E

AU - Kraemer, Helena

AU - Mesholam-Gately, Raquelle

AU - Seidman, Larry J.

AU - Stover, Ellen

AU - Weinberger, Daniel

AU - Young, Alexander S.

AU - Zalcman, Steven

AU - Marder, Stephen R.

PY - 2008/2

Y1 - 2008/2

N2 - Objective: The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia through a broadly based scientific evaluation of measures. Method: The MATRICS Neurocognition Committee evaluated more than 90 tests in seven cognitive domains to identify the 36 most promising measures. A separate expert panel evaluated the degree to which each test met specific selection criteria. Twenty tests were selected as a beta battery. The beta battery was administered to 176 individuals with schizophrenia and readministered to 167 of them 4 weeks later so that the 20 tests could be compared directly. Results: The expert panel ratings are presented for the initially selected 36 tests. For the beta battery tests, data on test-retest reliability, practice effects, relationships to functional status, practicality, and tolerability are presented. Based on these data, 10 tests were selected to represent seven cognitive domains in the MATRICS Consensus Cognitive Battery. Conclusions: The structured consensus method was a feasible and fair mechanism for choosing candidate tests, and direct comparison of beta battery tests in a common sample allowed selection of a final consensus battery. The MATRICS Consensus Cognitive Battery is expected to be the standard tool for assessing cognitive change in clinical trials of cognition-enhancing drugs for schizophrenia. It may also aid evaluation of cognitive remediation strategies.

AB - Objective: The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia through a broadly based scientific evaluation of measures. Method: The MATRICS Neurocognition Committee evaluated more than 90 tests in seven cognitive domains to identify the 36 most promising measures. A separate expert panel evaluated the degree to which each test met specific selection criteria. Twenty tests were selected as a beta battery. The beta battery was administered to 176 individuals with schizophrenia and readministered to 167 of them 4 weeks later so that the 20 tests could be compared directly. Results: The expert panel ratings are presented for the initially selected 36 tests. For the beta battery tests, data on test-retest reliability, practice effects, relationships to functional status, practicality, and tolerability are presented. Based on these data, 10 tests were selected to represent seven cognitive domains in the MATRICS Consensus Cognitive Battery. Conclusions: The structured consensus method was a feasible and fair mechanism for choosing candidate tests, and direct comparison of beta battery tests in a common sample allowed selection of a final consensus battery. The MATRICS Consensus Cognitive Battery is expected to be the standard tool for assessing cognitive change in clinical trials of cognition-enhancing drugs for schizophrenia. It may also aid evaluation of cognitive remediation strategies.

UR - http://www.scopus.com/inward/record.url?scp=40949097635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949097635&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2007.07010042

DO - 10.1176/appi.ajp.2007.07010042

M3 - Article

C2 - 18172019

AN - SCOPUS:40949097635

VL - 165

SP - 203

EP - 213

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -